Completed PHASE2 INTERVENTIONAL 1-arm NCT00003468

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

Phase II Study of Antineoplastons A10 and AS2-1 in Children With Low Grade Astrocytoma

Sponsor: Burzynski Research Institute

Interventions Antineoplaston therapy (Atengenal + Astugenal)

Updated 9 times since 2017 Last updated: Nov 3, 2023 Started: Jul 31, 1996 Primary completion: Jul 31, 2004 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Low Grade Astrocytomas and is currently completed. Burzynski Research Institute leads this study, which shows 9 recorded versions since 1996 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2023 — Dec 2023 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Burzynski Research Institute

Data source: Burzynski Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States